Company Profile

Abeona Therapeutics Inc (AKA: PlasmaTech Biopharmaceutcials Inc~Access Pharmaceuticals Inc~Chemex Corporation~Chemex Pharmaceuticals Inc)
Profile last edited on: 2/3/2023      CAGE: 6WXQ0      UEI: J7K5AGKFEL93

Business Identifier: Gene therapies for rare genetic diseases: potential cures for Sanfilippo syndrome types A and B
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1330 Avenue of the Americas 33rd Floor
New York, NY 20029
   (214) 905-5100
Location: Single
Congr. District: 12
County: Dallas

Public Profile

Briefly SBIR-active (2006), formerly known as PlasmaTech Biopharmaceuticals Inc and as Access Pharmaceuticals) - Abeona Therapeutics was originally trading on AMEX. Following delisting, the firm moved to OTC. The firm then issued another IPO on NASDAQ in December 2014 NASDAQ:ABEO). Now located in New York, NY, the firm has also a presence in Cleveland, OH and in Madrid, Spain. With technologies licensed from the Universities of Minnnesota, Nebraska and North Carolina, Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Lead programs are adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers, and clinicians. The company is also developing gene therapy for juvenile Batten disease (JBD); and for Fanconi anemia (FA) disorder using a CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including SDF AlphaT (alpha-1 protease inhibitor) for inherited COPD using its proprietary Salt Diafiltration (SDFT) ethanol-free process. The company is involved in marketing MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Timothy J Miller -- Chief Exec. Officer, Pres and Director

  Mark J Alvino -- Director

  Jeffrey B Davis -- Chief Operating Officer

  John W Dietrich

  Haiyan Fu -- Founder

  Kerry P Gray -- Former President

  Douglas McCarty -- Scientific Founder

  T Miller

  John V St John

  Alfred Stracher

  Stephen B Thompson -- Vice President Finance

  Harrison G Wehner -- Chief Financial Officer

  Philip Wise -- VP Business Development